OKYO Pharma Ltd ADR (OKYO NASDAQ) stock market data APIs
$2.9889
-0.26(-8.7%)
as of July 18, 2025
Try our APIs with
free plan!
OKYO Pharma Ltd ADR Financial Data Overview
Price chart is built with
Anychart
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Prev. Close
2.9889
Open
2.7321
High
3.0403
Low
2.7321
52 wk Range
0.8075-3.11
Market Cap
109 M
Shares Outstanding
37 424 K
EPS
-0.08
Beta
-4.299
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OKYO Pharma Ltd ADR data using free add-ons & libraries
Get OKYO Pharma Ltd ADR Fundamental Data
OKYO Pharma Ltd ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -10 351 442
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-29
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OKYO Pharma Ltd ADR News
New
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data
Investing.com - H.C. Wainwright has reiterated a Buy rating and $7.00 price target on OKYO Pharma Ltd. (NASDAQ:OKYO), representing a 136% upside from the current price of $2.96, following positive Pha...
OKYO Pharma reports results from Urcosimod trial
[Light beam is shining through retina and lens on eyesight exam] Zorica Nastasic/E+ via Getty Images * OKYO Pharma (NASDAQ:OKYO [https://seekingalpha.com/symbol/OKYO]) shared positive results from ...
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), dem...
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma p...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
